XRCC1 and prostate carcinoma: When evaluating the correlation between the XRCC1 Arg194Trp polymorphism and clinical outcomes in patients with HNSCC undergoing chemoradiation therapy (CCRT), Sambit Swarup Nanda et al reported that the incidence of acute radiation in HNSCC patients with the polymorphic variant XRCC1 who were treated with CCRT increased significantly, and others have stated that genetic polymorphisms in XRCC1 may affect the effect of radiotherapy in prostate cancer, breast cancer, and lung cancer.24, 31, 32, 33, 34, 35